Journal
CANCER CELL
Volume 18, Issue 1, Pages 9-10Publisher
CELL PRESS
DOI: 10.1016/j.ccr.2010.06.010
Keywords
-
Categories
Funding
- NIAMS NIH HHS [R01 AR043369] Funding Source: Medline
Ask authors/readers for more resources
A new clinical study reported in the New England Journal of Medicine unveils the long-awaited outcome of anti-CTLA-4 therapy for melanoma. It provides grounds for continued enthusiasm for cancer immunotherapy, deepens our thoughts on underlying mechanisms, and suggests exciting next steps.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
